TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05384847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thyroid hormone T3
Description: Participants will be admitted to the General Clinical Research Center (GCRC) for up to 5 days and will receive study medication twice a day. Participants will receive oral T3 under the supervision of the Principal Investigator or qualified co-investigators at the GCRC. The study drug will be given within 30 days after enrollment.
Study: NCT05752396

Intervention type: OTHER
Intervention: Offset Analgesia
Description: Offset analgesia (OFA) procedure evaluates the disproportionate change in heat pain sensitivity after a slight decrease in stimulus intensity. This psychophysical paradigm investigates inhibitory pain modulation processes.
Study: NCT05450939

Intervention type: DIAGNOSTIC_TEST
Intervention: Signal intensity gradient
Description: In time-of-flight (TOF) MRA, The signal intensities at the iso-point (Φa; signal intensity at position A \[Xa\] along the arterial contour line) and at the inner point (Φb; signal intensity at position B \[Xb\]) were calculated by using a trilinear interpolation algorithm based on the positions and signal intensities in the eight neighboring voxels. The signal intensities of TOF-MRA were normalized to eliminate the offset and scale effects across the MRA datasets of participants. For each iso-point (position A), the SIG was calculated from the difference in signal intensities between points A and B as follows:~Scalar SIG, SI/mm = (Φb - Φa) / │Xb - Xa│ (1)~Vector SIG, SI/mm = (Φb - Φa) n / │Xb - Xa│ (2)

Intervention type: DIAGNOSTIC_TEST
Intervention: Signal intensity gradient
Description: In time-of-flight (TOF) MRA, The signal intensities at the iso-point (Φa; signal intensity at position A \[Xa\] along the arterial contour line) and at the inner point (Φb; signal intensity at position B \[Xb\]) were calculated by using a trilinear interpolation algorithm based on the positions and signal intensities in the eight neighboring voxels. The signal intensities of TOF-MRA were normalized to eliminate the offset and scale effects across the MRA datasets of participants. For each iso-point (position A), the SIG was calculated from the difference in signal intensities between points A and B as follows:~Scalar SIG, SI/mm = (Φb - Φa) / │Xb - Xa│ (1)~Vector SIG, SI/mm = (Φb - Φa) n / │Xb - Xa│ (2)
Study: NCT04910399

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blue fish hydrolysate
Description: The experimental product is a dietary supplement composed of a hydrolysate of fatty blue fish containing low molecular weight peptides and n-3 polyunsaturated fatty acids.~One of the two study groups (28 volunteers) will take 4 capsules of the active product (blue fish hydrolysate), for 90 days.~Each day the capsules will be taken as followed : 2 capsules in the morning and 2 capsules in the evening.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo product containing mainly maltodextrin is presented in the same form as the active product, so that people handling the product cannot distinguish between them. The placebo is flavoured in order to have a fishy smell just like the active product.~One of the two study groups (28 volunteers) will take 4 capsules of placebo per day, for 90 days.Each day the capsules will be taken as followed : 2 capsules in the morning and 2 capsules in the evening.
Study: NCT05851170

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The use of warm compresses and almond oil on the perineum during second stage
Description: Hot water from the tap at a temperature of (45-590c) will be poured into a container, and will be changed every 15 minutes.~Timing of the start: when the baby's head descends in the pelvic canal and the woman feels the need to push The intervention: warm compresses will be attached to the perineum between the pressures During the pressing - almond oil will be applied. Meanwhile, the compresses will be returned to a bowl containing hot water. Every 15 minutes until birth the water will be replaced with hot water at an initial temperature of 45-590c.~It is necessary to use compresses for a minimum of 10 minutes, and a maximum of 30 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Use of almond oil use (routine care) during second stage
Description: Routine care in the department is the use of almond oil during the second stage of pregnancy, during pushing.
Study: NCT05554991

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HMO
Description: Composition comprising of HMO

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo supplementation having the same appearance and dosing regimen as the intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parental reassurance and support
Description: Both groups will receive standardized written materials to provide parental reassurance and support, in alignment with local clinical practice

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Parental reassurance and support
Description: Both groups will receive standardized written materials to provide parental reassurance and support, in alignment with local clinical practice
Study: NCT05384847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thyroid hormone T3
Description: Participants will be admitted to the General Clinical Research Center (GCRC) for up to 5 days and will receive study medication twice a day. Participants will receive oral T3 under the supervision of the Principal Investigator or qualified co-investigators at the GCRC. The study drug will be given within 30 days after enrollment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thyroid hormone T3
Description: Participants will be admitted to the General Clinical Research Center (GCRC) for up to 5 days and will receive study medication twice a day. Participants will receive oral T3 under the supervision of the Principal Investigator or qualified co-investigators at the GCRC. The study drug will be given within 30 days after enrollment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: The control group will have testing and study procedures as per protocol but will not be admitted to the General Clinical Research Center (GCRC) and will not receive the study medication. After completion of phase I, participants will be permitted to enroll in Phase II.
Study: NCT05824884

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Visual Feedback
Description: Visual progress feedback and words of positive affirmation will be presented triggered by checkpoints set in the VR-height-exposure.
Study: NCT05752396

Intervention type: OTHER
Intervention: Offset Analgesia
Description: Offset analgesia (OFA) procedure evaluates the disproportionate change in heat pain sensitivity after a slight decrease in stimulus intensity. This psychophysical paradigm investigates inhibitory pain modulation processes.

Intervention type: OTHER
Intervention: Offset Analgesia
Description: Offset analgesia (OFA) procedure evaluates the disproportionate change in heat pain sensitivity after a slight decrease in stimulus intensity. This psychophysical paradigm investigates inhibitory pain modulation processes.

Intervention type: OTHER
Intervention: Spatial Summation
Description: Spatial summation (SS) procedure evaluates the change in heat pain sensitivity when applying two painful stimuli simultaneously compared to one stimulus alone. This psychophysical paradigm investigates facilitatory pain modulation processes.

Intervention type: OTHER
Intervention: Spatial Summation
Description: Spatial summation (SS) procedure evaluates the change in heat pain sensitivity when applying two painful stimuli simultaneously compared to one stimulus alone. This psychophysical paradigm investigates facilitatory pain modulation processes.

Intervention type: OTHER
Intervention: Spatial Summation
Description: Spatial summation (SS) procedure evaluates the change in heat pain sensitivity when applying two painful stimuli simultaneously compared to one stimulus alone. This psychophysical paradigm investigates facilitatory pain modulation processes.

Intervention type: OTHER
Intervention: Temporal Summation
Description: Temporal summation (TS) procedure evaluates the change in mechanical pain sensitivity after exposure to a series of noxious stimuli of the same intensity. This psychophysical paradigm investigates facilitatory pain modulation processes.

Intervention type: OTHER
Intervention: Temporal Summation
Description: Temporal summation (TS) procedure evaluates the change in mechanical pain sensitivity after exposure to a series of noxious stimuli of the same intensity. This psychophysical paradigm investigates facilitatory pain modulation processes.

Intervention type: OTHER
Intervention: Temporal Summation
Description: Temporal summation (TS) procedure evaluates the change in mechanical pain sensitivity after exposure to a series of noxious stimuli of the same intensity. This psychophysical paradigm investigates facilitatory pain modulation processes.
Study: NCT05500235

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smart phone based training
Description: The study team will acquaint headmasters with the Tobacco Free Teachers-Tobacco Free Society (TFT-TFS) program and the smartphone training app. Headmasters will receive six monthly trainings on smartphones, including brief videos followed by quizzes with feedback, discussion forums to promote peer learning, demonstration of techniques, and the ability to review the content as needed. Headmasters will implement TFT-TFS at monthly school meetings with teachers and parents. TFT-TFS consists of four program components: (1) six group discussions with teachers, (2) cessation support and referrals to government resources, (3) posting six thematic tobacco control posters in the school, and (4) implementing a school tobacco policy. These four components incorporate the program's six themes: Teachers as Role Models; Health Effects of Tobacco; Motivation to Quit Tobacco Use; Skills to Quit Tobacco and to Help Others Quit; Dealing with Withdrawal; and Maintenance and Celebration.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In person training
Description: Headmasters will receive three face-to-face trainings, each 60-75 minutes long and held at convenient locations. The study team will introduce headmasters to the TFT-TFS program and teach participants how to use paper-based materials. The trainings will encourage participants to discuss successes and come up with solutions to overcome challenges. Headmasters will implement TFT-TFS at monthly school meetings with teachers and parents. TFT-TFS consists of four program components: (1) 6 group discussions with teachers, (2) cessation support and referrals to government resources, (3) posting six thematic tobacco control posters in the school, and (4) implementing a school tobacco policy. These four components incorporate the program's six themes: Teachers as Role Models; Health Effects of Tobacco; Motivation to Quit Tobacco Use; Skills to Quit Tobacco and to Help Others Quit; Dealing with Withdrawal; and Maintenance and Celebration.
Study: NCT05268523

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education and Strategies Intervention
Description: Sessions will be led by registered therapists and clinicians in the fields of psychology, rheumatology, cardiology and neurology. The sessions will be comprised of educational presentations on the nature of persisting symptoms after COVID-19 and associated recommendations for self-management.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Skills Intervention
Description: The Mindfulness Skills Intervention is an 8-week program designed to provide an introduction to some basic mindfulness skills. Each session begins with a brief breath focus practice followed by discussion of the experience and sharing/discussion of the previous week including participants' experiences. Each session also includes some didactics, and a new, related mindfulness skill is introduced and practiced, followed by another discussion.
Study: NCT06337968

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Circum-psoas Block
Description: Ultrasound-guided circum-psoas block with 40 mL of treatment drug (Ropivacaine 0.2% \[local anesthetic\]) 30 minutes prior to induction of anesthesia.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham block
Description: Perform ultrasound scanning without puncture.
Study: NCT05968703

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined STN+NBM DBS
Description: This intervention is a 4-lead deep brain stimulation approach targeting the Subthalamic Nucleus (STN) and Nucleus Basalis of Meynert (NBM)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined STN+NBM DBS
Description: This intervention is a 4-lead deep brain stimulation approach targeting the Subthalamic Nucleus (STN) and Nucleus Basalis of Meynert (NBM)
Study: NCT05512286

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Description: Radiotherapy followed by mastectomy and DIEP flap reconstruction
Study: NCT05824884

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual Feedback
Description: Visual progress feedback and words of positive affirmation will be presented triggered by checkpoints set in the VR-height-exposure.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-efficacy enhancement:
Description: specific instructions regarding the retrieval of mastery experiences during exposure will be given (modified version of the procedure used in Raeder et al. 2019).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-efficacy enhancement:
Description: specific instructions regarding the retrieval of mastery experiences during exposure will be given (modified version of the procedure used in Raeder et al. 2019).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: placebo intervention
Description: specific instructions regarding the retrieval of the exposure session will be given without an emphasis on personal mastery experience (modified version of the procedure used in Raeder et al. 2019).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo intervention
Description: specific instructions regarding the retrieval of the exposure session will be given without an emphasis on personal mastery experience (modified version of the procedure used in Raeder et al. 2019).
Study: NCT05512286

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Postmastectomy radiotherapy
Description: Radiotherapy after mastectomy and DIEP flap reconstruction
Study: NCT05824884

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No visual feedback
Description: Participants can not trigger any checkpoints during VR and therefore not receive any progress feedback or positive affirmation.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No visual feedback
Description: Participants can not trigger any checkpoints during VR and therefore not receive any progress feedback or positive affirmation.
Study: NCT05112835

Intervention type: OTHER
Intervention: brolucizumab
Description: There is no treatment allocation. The decision to administer brolucizumab is made by the treating physician independent of the study, prior to the inclusion of the patient into the study
Study: NCT05160805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONL1204 Ophthalmic solution (Dose A)
Description: Liquid formulation administered by intravitreal (IVT) injection
Study: NCT05998031

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: A neuroConn MR-safe 1x1 tDCS stimulator will be used to apply 12 minutes of 2.0 mA electrical current, with 30 seconds ramps up and 30 seconds ramps down. The electrical current will be applied by using two carbon rubber electrodes (one anode, one cathode) with added ten20 conductive paste. The electrode+paste will be affixed on the participant's scalp over the frontal cortices at F3 and F4 location (EEG 10-20 system). Inflow of current (anode) will occur at F4 location, and outflow of current will occur at F3 (cathode).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham tDCS
Description: Sham stimulation will be performed with the same 1x1 device. Participants will receive 2 mA of direct current stimulation for 30 seconds with 30 seconds ramps up and down. This provides the tingling and prickling sensation on the scalp associated with tDCS while prevent delivering sufficient current (12 minutes) to penetrate the skull and stimulate the brain. Prep in sham conditions will be identical to active stimulation conditions. For each stimulation condition (active, sham), each participant will perform three runs of N-back working memory task (baseline/pre-stimulation, during stimulation, and after/post-stimulation) as detailed below. Sham efficacy will be evaluated as a direct comparison in N-back performance and connectivity results in active group versus sham group.
Study: NCT05160805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONL1204 Ophthalmic solution (Dose B)
Description: Liquid formulation administered by intravitreal (IVT) injection

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: A sham procedure looks like a real injection into the eye but does not penetrate the eye and it does not have any study drug. The procedure is done by touching the eye surface with a syringe without a needle.
Study: NCT05898399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART6043
Description: ART6043 will be given orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART6043
Description: ART6043 will be given orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART6043
Description: ART6043 will be given orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART6043
Description: ART6043 will be given orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART6043
Description: ART6043 will be given orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib will be given orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib will be given orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib will be given orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be given orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be given orally.
Study: NCT05683639

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: warming of the follicular aspiration needle
Description: the follicular aspiration needle will be heated overnight before the ovarian aspiration procedure.
Study: NCT05203822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib (HydroChloride hydrate)
Description: Participants received Tepotinib (Hydrochloride hydrate) Film-coated tablet with food on Day 1 and 12 in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Participants received Itraconazole Hard-gelatin capsule with food once daily at the same time in the morning from Day 8 to Day 18; on Day 12 itraconazole is administered concomitantly with tepotinib.
Study: NCT05534854

Intervention type: GENETIC
Intervention: Gene test
Description: Next generation sequencing of blood, urine and/or benign and malignant tissue of patients and family members with known or suspected heritable kidney cancer syndromes, including VHL and HLRCC Disease.

Intervention type: GENETIC
Intervention: Gene test
Description: Next generation sequencing of blood, urine and/or benign and malignant tissue of patients and family members with known or suspected heritable kidney cancer syndromes, including VHL and HLRCC Disease.
Study: NCT05898399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be given orally.
Study: NCT05573295

Intervention type: OTHER
Intervention: Diagnostic Test: Willems method
Description: Willems method measures the developmental stages of the seven left permanent mandibular teeth and is frequently used for dental age estimation. The score of each stage is allocated, and the sum of the scores provides an evaluation of the subject's dental maturity.
Study: NCT05534854

Intervention type: GENETIC
Intervention: Gene test
Description: Next generation sequencing of blood, urine and/or benign and malignant tissue of patients and family members with known or suspected heritable kidney cancer syndromes, including VHL and HLRCC Disease.
Study: NCT05182242

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collection of clinical data
Description: family history, clinical data, ultrasound and all other data necessary for the study on a e-CRF (CleanWEB), allowing the collection of the family tree, and if necessary photographic elements.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Collection of samples
Description: Collected during fetal and blood sampling performed as part of care for ACPA:~* 4 Streck tubes maximum for the pregnant woman for NIPD-Exome, collected prior to invasive fetal sampling~* 1 additional vial of fetal sample (amniotic fluid or fetal blood) and 1 EDTA tube for each of the two parents

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: within the framework of the pilot study (optional): questionnaires (about 20 minutes) for the evaluation of the experience, perceptions, impact of the analyses on the decision, satisfaction and concerns regarding exome sequencing (ES) and its results, opinion on certain types of results currently not reported, anxiety, possible psychological difficulties

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parent interviews
Description: as part of the pilot study (optional): interview (about 1 hour) with a sociologist to explore perceptions of ES and the impact of the results, expectations about certain types of results that are not currently available, emotional situation, position regarding the continuation of the pregnancy

Intervention type: OTHER
Group type: OTHER
Intervention: Professional interview and focus groups
Description: Interview (approximately 45 minutes) to understand how the decision is formed Focus groups to help clarify whether the Variants of Unknown Significance (VUSs) should potentially be returned to the clinicians, or even the patient via the clinician
Study: NCT05234476

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation plus Savoring
Description: Individuals in this intervention will complete two sessions of behavioral activation, where they will be provided psychoeducation on behavioral models of mood, schedule activities, and discuss barriers to completion. Additionally, they will practice savoring as a cognitive strategy to increase positive emotions with a study therapist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Empathic Listening
Description: Individuals in the active control condition will complete two sessions of reflecting on tracking their mood and empathic listening with a study therapist.